[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"behet-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:behet-disease":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,54,85],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100388150","deployment-o-the-multidisciplinary-prospective-cohort-imminent-100388150",false,"NCT04334031","Deployment o the Multidisciplinary Prospective Cohort Imminent","IMMINeNT","Inclusion Criteria:\n\n* Patient followed for their IMID in one of the departments of the Lille University Hospital participating in the study (dermatology, internal medicine, neurology, pneumology and rheumatology)\n* Social insured\n* Have the capacity to understand the study requirements, provide written informed consent, and comply with the study data collection procedures.\n\nExclusion Criteria:\n\n* Administrative reasons: inability to receive informed information, inability to participate in the entire study, lack of coverage by the social security system.\n* Pregnant or breastfeeding woman\n* Persons deprived of liberty\n* Protected minors or adults\n* Persons who have refused or are incapable of giving informed consent\n* Persons in Emergency Situations","ALL","18 Years",{"count":19,"type":20},2200,"ESTIMATED","INTERVENTIONAL",[23],"NA","Immune-mediated inflammatory diseases (IMIDs) most often affect young patients and have high impact on morbidity and mortality with a significant alteration in the quality of life of patients with professional, social and emotional repercussions.\n\nBeyond this burden, IMIDs share many common pathophysiological mechanisms and treatments, known as \"targeted therapies\". Despite progress in this field, much remains to be done in clinical, therapeutic and fundamental research to address the efficacy, resistance and side-effects of treatment.\n\nThese similarities between IMIDs have led the FHU IMMINeNT to propose the creation of a prospective, multidisciplinary clinical-biological database (IMMINeNT cohort), associated to a biobank, of patients with IMIDs. The main objectives of this database will be to identify new prognostic and therapeutic biomarkers in order to develop new therapeutic targets and biomarkers, to identify prognostic factors and determinants related to the activity, severity and quality of life of patients with IMIDs as well as to the response and tolerance to treatment.",[26,27,28,29,30,31,32,33,34],"Chronic Inflammatory Disease","Angioedema","Severe Asthma","Lupus","Atopic Dermatitis","Psoriatic Arthritis","Multiple Sclerosis","Systemic Sclerosis","Behçet Disease",[36,37,38,39,40],"Immune Mediated Inflammatory Diseases (IMIDs)","biomarker","cohort study","quality of life","disease severity","RECRUITING","2026-04-28",{"date":44,"type":45},"2026-05-05","ACTUAL",{"date":47,"type":45},"2020-07-20",{"date":49,"type":20},"2031-07-21",{"name":51,"class":52},"University Hospital, Lille","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":16,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":4,"studyType":21,"phases":66,"briefSummary":68,"conditions":69,"keywords":70,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":77,"completionDateStruct":79,"leadSponsor":81,"locationsCount":84},"100403037","phase-3-apremilast-pediatric-study-in-children-with-active-oral-ulcers-associated-with-behets-disease-100403037","NCT04528082","Apremilast Pediatric Study in Children With Active Oral Ulcers Associated With Behçet's Disease","A Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Study, Followed by an Active Treatment Phase to Evaluate the Efficacy and Safety of Apremilast in Children From 2 to Less Than 18 Years of Age With Active Oral Ulcers Associated With Behçet's Disease (BEAN)","BEAN","Key Inclusion Criteria\n\n* Male or Female participants 2 to \\\u003C 18 years of age at randomization.\n* Diagnosed with BD meeting the ISGBD criteria at any time prior to the screening visit.\n* Oral ulcers that occurred ≥ 3 times within the 12-month period prior to the screening visit.\n* Participant must have ≥ 2 oral ulcers at both the screening visit and on day 1.\n* Participant has had prior treatment with ≥ 1 non-biologic BD therapy, such as, but not limited to, topical corticosteroids or systemic treatment.\n\nKey Exclusion Criteria\n\n* Behçet's disease-related active major organ involvement - pulmonary (eg, pulmonary artery aneurysm), vascular (eg, thrombophlebitis), gastrointestinal (eg, ulcers along the gastrointestinal tract), or CNS (eg, meningoencephalitis) manifestations, or ocular lesions (eg, uveitis) requiring immunosuppressive therapy; however:\n\n  * Previous major organ involvement is allowed if it occurred ≥1 year prior to the screening visit and is not active at time of enrollment\n  * Participants with mild BD-related ocular lesions not requiring systemic immunosuppressive therapy are allowed\n  * Participants with BD-related arthritis and BD-skin manifestations are also allowed.\n* Previous exposure to biologic therapies for the treatment of BD oral ulcers, previous biologic exposure is allowed for other indications (including other manifestations of BD).","2 Years","17 Years",{"count":65,"type":20},60,[67],"PHASE3","The aim of this study is to estimate the efficacy of apremilast compared to placebo in the treatment of oral ulcers in pediatric participants from 2 to \\\u003C 18 years of age with oral ulcers associated with Behçet's disease (BD) through week 12.",[34],[71,72,73],"Behçet's Disease","Oral ulcers","Apremilast","2025-11-26",{"date":76,"type":45},"2025-12-01",{"date":78,"type":45},"2021-09-09",{"date":80,"type":20},"2030-12-17",{"name":82,"class":83},"Amgen","INDUSTRY",27,{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":92,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":96,"phases":4,"briefSummary":97,"conditions":98,"keywords":99,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":53},"100550784","thrombophilia-and-thrombosis-in-behets-disease-100550784","NCT06451575","Thrombophilia and Thrombosis in Behçet's Disease","Thrombophilia and Tendency to Thrombosis in Behçet's Disease","Inclusion Criteria:\n\n1. 18-70 years old\n2. Patients who fulfil the international diagnostic criteria for Behçet's disease\n3. Those who accepted the consent form\n\nExclusion Criteria:\n\n1. Those under 18 years of age\n2. accompanied by another inflammatory dermatological disease\n3. Pregnancy and breastfeeding\n4. Those who use drugs that increase the tendency to thrombosis -",true,"70 Years",{"count":95,"type":20},200,"OBSERVATIONAL","Behçet's disease (BD) is a systemic vasculitis of unknown cause, affecting mainly young adults. Vasculopathy has been reported in 16.8-51.5% of cases. Genetic, infectious factors, environmental factors, presence of autoantibodies, endothelial pathologies and hypercoagulability are responsible for the etiopathogenesis of BD. The main involvements responsible for morbidity and mortality in Behçet's disease are ocular, major cardiovascular and neurological involvements. Although there is an increased thrombotic risk in the etiopathogenesis of Behçet's disease, the cellular and molecular mechanisms are not fully understood. Although endothelial dysfunction due to inflammation has been shown to be the primary cause of vascular damage in Behçet's disease, some clinical evidence suggests that hypercoagulable states also contribute to thrombosis. The most common form of vascular involvement in Behçet's disease is deep vein thrombosis in the lower extremities. Arterial occlusion mostly affects the subclavian and pulmonary arteries. Although arterial involvement is rarer than venous involvement in Behçet's disease, morbidity and mortality are higher than venous involvement.\n\nAlthough an increased thrombotic risk is mentioned in the etiopathogenesis of Behçet's disease, it is still controversial whether vasculitis or susceptibility to hypercoagulability plays a role in the pathogenesis of venous thrombosis. In addition, there are very few studies in the literature in which all thrombophilic parameters were analysed. Again, there is no recent study on this subject. The aim of our study is to determine the risk of hypercoagulability in Behçet's disease patients with vascular involvement, which has a highly mortal course.",[34],[100,101,102],"thrombosis","thrombophilia","Behcet's disease","2024-06-04",{"date":105,"type":45},"2024-06-11",{"date":107,"type":45},"2023-06-01",{"date":109,"type":20},"2024-09-01",{"name":111,"class":52},"Ataturk University"]